A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
Public ClinicalTrials.gov record NCT00009737. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Randomized Phase III Study Comparing Xeloda (Capecitabine) With IV Bolus 5-Fluorouracil in Combination With Low-Dose Leucovorin as Adjuvant Chemotherapy in Patients Who Underwent Surgery for Dukes C Colon Cancer
Study identification
- NCT ID
- NCT00009737
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 1,987 participants
Conditions and interventions
Conditions
Interventions
- 5-Fluorouracil Drug
- Capecitabine [Xeloda] Drug
- Leucovorin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 1998
- Primary completion
- Mar 31, 2004
- Completion
- Mar 31, 2004
- Last update posted
- Jun 21, 2016
1998 – 2004
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Phoenix | Arizona | 85012 | — |
| Not listed | Fountain Valley | California | 92708 | — |
| Not listed | Los Angeles | California | 90089 | — |
| Not listed | Hartford | Connecticut | 06102-5037 | — |
| Not listed | Miami | Florida | 33176 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Columbia | Missouri | 65203 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Buffalo | New York | 14263 | — |
| Not listed | Cleveland | Ohio | 44195 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Nashville | Tennessee | 37203-1632 | — |
| Not listed | Austin | Texas | 78705 | — |
| Not listed | Tyler | Texas | 75701 | — |
| Not listed | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 116 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00009737, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2016 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00009737 live on ClinicalTrials.gov.